Skip to main content

Adult

5
Pipeline Programs
7
Companies
11
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Grit Biotechnology
Grit BiotechnologyChina - Shanghai
7 programs
1
1
GT101 injectionPhase 21 trial
GT101Phase 11 trial
Autologous tumor infiltrating lymphocyte injection（GT201）N/A1 trial
GT201 injectionN/A1 trial
GT201 injection in combination with teraplizumab injectionN/A1 trial
+2 more programs
Active Trials
NCT06191900Terminated4Est. Dec 2025
NCT06519669Terminated2Est. Dec 2025
NCT06235242Terminated2Est. Dec 2025
+4 more trials
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
MOA-728Phase 11 trial
Active Trials
NCT00387491Completed16Est. Oct 2006
Mochida Pharmaceutical
1 program
1
MR1817Phase 11 trial
Active Trials
NCT00960180Completed64Est. Jan 2011
Prevail Therapeutics
1 program
1
capecitabinePhase 11 trial
Active Trials
NCT00052273Completed16Est. Oct 2005
Physical Sciences
Physical SciencesMA - Andover
1 program
Healthy Lifestyle or Pro-health Obsession During the PandemicN/A1 trial
Active Trials
NCT04432038Unknown50,000Est. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Grit BiotechnologyGT101 injection
Grit BiotechnologyGT101
Mochida PharmaceuticalMR1817
Bausch HealthMOA-728
Prevail Therapeuticscapecitabine
Grit BiotechnologyGT201 injection
Grit BiotechnologyGT307 injection
Grit BiotechnologyGT307 injection
Grit BiotechnologyGT201 injection in combination with teraplizumab injection
Grit BiotechnologyAutologous tumor infiltrating lymphocyte injection（GT201）
Physical SciencesHealthy Lifestyle or Pro-health Obsession During the Pandemic

Clinical Trials (11)

Total enrollment: 50,243 patients across 11 trials

NCT06241781Grit BiotechnologyGT101 injection

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Start: Apr 2024Est. completion: Jan 202783 patients
Phase 2Recruiting
NCT06077903Grit BiotechnologyGT101

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

Start: Jul 2021Est. completion: Jul 202520 patients
Phase 1Recruiting
NCT00960180Mochida PharmaceuticalMR1817

Study Evaluating Single Ascending Doses of MR1817

Start: Jul 2010Est. completion: Jan 201164 patients
Phase 1Completed
NCT00387491Bausch HealthMOA-728

Dose Ranging Study in Healthy Methadone Maintenance Subjects

Start: Jun 2006Est. completion: Oct 200616 patients
Phase 1Completed
NCT00052273Prevail Therapeuticscapecitabine

LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

Start: Dec 2002Est. completion: Oct 200516 patients
Phase 1Completed
NCT06519669Grit BiotechnologyGT201 injection

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

Start: Jul 2024Est. completion: Dec 20252 patients
N/ATerminated
NCT06453057Grit BiotechnologyGT307 injection

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

Start: Jul 2024Est. completion: Jun 202718 patients
N/ARecruiting
NCT06819280Grit BiotechnologyGT307 injection

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

Start: Jun 2024Est. completion: May 202718 patients
N/ARecruiting
NCT06235242Grit BiotechnologyGT201 injection in combination with teraplizumab injection

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

Start: Feb 2024Est. completion: Dec 20252 patients
N/ATerminated
NCT06191900Grit BiotechnologyAutologous tumor infiltrating lymphocyte injection（GT201）

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

Start: Jun 2023Est. completion: Dec 20254 patients
N/ATerminated
NCT04432038Physical SciencesHealthy Lifestyle or Pro-health Obsession During the Pandemic

Healthy Lifestyle or Pro-health Obsession During the Pandemic

Start: Jun 2020Est. completion: Jun 202150,000 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 50,243 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.